• Kiyoto Koibuchi, Moriatsu Miyagi, Taichi Arai, Toshiyuki Aoki, Atsushi Aikawa, and Ken Sakai.
• Department of Nephrology and Dialysis, Saiseikai Yokohama-City Eastern Hospital, Kanagawa, Japan.
• Nephrology (Carlton). 2015 Dec 1; 20 Suppl 4: 22-8.

AimErythropoiesis-stimulating agent (ESA) treatment during the predialysis period can be a strategy to reduce cardiac mortality soon after initiation of dialysis. In this study, we compared the efficacy of continuous erythropoietin receptor activator (CERA) and darbepoetin alfa (DA) in patients with chronic kidney disease (CKD) over 6 months prior to initiation of dialysis.MethodsThis study was a retrospective propensity score-matched study conducted at a single center in Japan that analyzed the effects of CERA and DA therapy on haemoglobin (Hb) changes, ESA resistance index (ERI) changes, and interval of ESA administration during a 6-month observation period prior to initiation of dialysis. Propensity scores were used for matching the patients included in the CERA and DA groups.ResultsAmong 680 screened, 74 pairs of patients (one in each group) were included in the present analysis after propensity score matching. Mean Hb significantly decreased over 6 months in the DA group compared to that in the CERA group (-0.70 ± 0.23 vs. -0.33 ± 0.22). In the DA group, mean ERI was significantly increased at 4, 3, 2, and 1 month before dialysis and initiation of dialysis, while in the CERA group, mean ERI was significantly increased only at 1 month before dialysis and initiation of dialysis. Moreover, patients administered CERA were required to visit the hospital significantly less frequently for ESA administration than those administered DA.ConclusionOur study showed that CERA may be more effective than DA for management of anaemia during the predialysis period in CKD patients.© 2015 Asian Pacific Society of Nephrology.

28 keywords...

hide…